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Abstract
Background: The BRCA1 gene plays an important role in the maintenance of genomic stability. BRCA1 inactivation
contributes to breast cancer tumorigenesis. An increasing number of transcription factors have been shown to
regulate BRCA1 expression. c-Myc can act as a transcriptional activator, regulating up to 15% of all genes in the
human genome and results from a high throughput screen suggest that BRCA1 is one of its targets. In this report,
we used cultured breast cancer cells to examine the mechanisms of transcriptional activation of BRCA1 by c-Myc.
Methods: c-Myc was depleted using c-Myc-specific siRNAs in cultured breast cancer cells. BRCA1 mRNA expression
and BRCA1 protein expression were determined by quantitative RT-PCR and western blot, respectively and BRCA1
promoter activities were examined under these conditions. DNA sequence analysis was conducted to search for
high similarity to E boxes in the BRCA1 promoter region. The association of c-Myc with the BRCA1 promoter in vivo
was tested by a chromatin immunoprecipitation assay. We investigated the function of the c-Myc binding site in
the BRCA1 promoter region by a promoter assay with nucleotide substitutions in the putative E boxes. BRCA1-
dependent DNA repair activities were measured by a GFP-reporter assay.
Results: Depletion of c-Myc was found to be correlated with reduced expression levels of BRCA1 mRNA and
BRCA1 protein. Depletion of c-Myc decreased BRCA1 promoter activity, while ectopically expressed c-Myc increased
BRCA1 promoter activity. In the distal BRCA1 promoter, DNA sequence analysis revealed two tandem clusters with
high similarity, and each cluster contained a possible c-Myc binding site. c-Myc bound to these regions in vivo.
Nucleotide substitutions in the c-Myc binding sites in these regions abrogated c-Myc-dependent promoter
activation. Furthermore, breast cancer cells with reduced BRCA1 expression due to depletion of c-Myc exhibited
impaired DNA repair activity.
Conclusions: The distal BRCA1 promoter region is associated with c-Myc and contributes to BRCA1 gene activation.
Background
The human breast cancer susceptibility gene 1 product,
BRCA1 is involved in important cellular processes, includ-
ing DNA repair, and loss of BRCA1 can result in genomic
instability. Loss of BRCA1 expression occurs in a subset of
breast cancer cases, and inherited mutations of the BRCA1
gene account for about 5% of all breast cancer cases [1-8].
The regulation of BRCA1 expression has been studied
extensively, including investigations of alternative mechan-
isms for reduced expression of BRCA1 in sporadic cases
[9,10]. A set of transcription factors and/or co-factors has
been shown to regulate BRCA1 expression through a
region in close proximity to the BRCA1 transcription start
site. This proximal promoter region of BRCA1 is bidirec-
tional and includes a 218 bp intergenic region between the
BRCA1 and NBR2 genes [11]. Within this region, it has
been demonstrated that a short segment (-204 to -148)
relative to BRCA1 exon 1a start site may be responsible for
BRCA1 promoter activities [12]. Another report confirmed
these findings using a different strategy of deletion analysis
and showed that a slightly shorter region (-202 to -166)
was required for BRCA1 promoter activation [13,14].
Further studies of this region (-202 to -166) revealed two
sub-elements: 1) a RIBS element (-204 to -182) that binds
to and is activated by a GABPa/b complex [15] and 2) a
CREB/ATF1 element (-174 to -167) that acts as a constitu-
tive transcriptional activation element bound by CREB
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binds to two regions, -41 to -31 and -21 to -11, and acti-
vates or represses BRCA1 expression depending on the co-
factors recruited [18,19], BRCA1 itself has been shown to
be one of the co-factors [20]. An element (-40 to -25) that
overlaps one of the E2F binding sites can be bound and
activated by 53BP1 in a sequence-specific manner and
functions as a positive regulatory element [21]. An ER-a
transcription complex binds an AP1 element (+246 to
+250) and activates BRCA1 transcription upon estrogen
stimulation [22]. This ER-a dependent activation can be
modulated by an aromatic hydrocarbon receptor complex
that binds two consecutive xenobiotic-responsive elements
located upstream of the ER-a binding region (+17 to +21
and +175 to +179) [23]. A relatively long segment in a 5
kb region in BRCA1 intron 2 that is highly conserved in
multiple species contains a CNS-1 (Conserved Nucleotide
Site-1) and CNS-2, which appear to act as repression and
activation elements, respectively [24].
c-Myc is a transcription factor involved in growth, pro-
liferation, differentiation, and apoptosis of cells and regu-
lates up to 15% of human genes [25]. c-Myc regulates
transcription through several mechanisms, and cis-regu-
latory elements modulate specific subsets of c-Myc tar-
gets. One of the cis-regulatory elements, E box, is
common in c-Myc targeted genes [26]. Serial analysis of
gene expression performed after adenoviral expression of
c-Myc in primary human umbilical vein endothelial cells
has implicated BRCA1 as one of the activated gene tar-
gets for c-Myc [27]. However, it was not clear whether c-
Myc could transcriptionally regulate BRCA1 expression
through a cis-regulatory element, particularly in breast
cancer cells. In this report, we show that depletion of c-
Myc is correlated with a reduction in BRCA1 mRNA and
BRCA1 protein levels and decreased BRCA1 promoter
activities were observed in the cells following depletion
of c-Myc. On the other hand, ectopic expression of c-
Myc activated BRCA1 promoter activities. DNA sequence
analysis revealed two novel E boxes within the distal
BRCA1 promoter. A chromatin immunoprecipitation
assay demonstrated that c-Myc binds to these E boxes in
vivo. Furthermore, we show that BRCA1 promoter/repor-
ters containing nucleotide substitutions in these E boxes
abrogate their c-Myc dependent activation. These data
s u g g e s tt h a tc - M y ca c t i v a t e sBRCA1 expression through
the E boxes in the distal BRCA1 promoter region. Finally
w eo b s e r v e dt h a tc e l l st r e a t e dw i t hc - M y cs p e c i f i cs i R -
NAs had reduced DNA repair activity, a biological pro-
cess associated with BRCA1.
Methods
Cell culture
Breast cancer cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). MCF-7
cells (ATCC: HTB-22) were cultured in DMEM (Media-
tech, Inc., Manassas, VA) supplemented with 10% fetal
bovine serum (Lonza, Inc, Allendale, NJ) and 1% anti-
biotic-antimycotic solution (Mediatech Inc.). MDA-MB-
231 cells (ATCC: HTB-26) were cultured in RPMI1640
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (Lonza, Inc.) and 1% antibiotic-antimyco-
tic solution (Mediatech, Inc.).
Plasmid construction
A vector containing human c-Myc cDNA was obtained
from ATCC (ATCC: 5233860) and used to construct a
c-Myc-GFP expression vector designated pMYC-GFP.
The full length c-Myc protein coding DNA fragment
was inserted in the 5’ end of GFP under the control of
the cytomegalovirus (CMV) promoter. First the full-
length coding region of c-Myc was amplified by PCR
using primers (5’-TCCCGCGACG ATGCCCCTCA AC
GTTAGCTTCA-3’ and 5’-CACAAGAGTT CCGTAG
CTGT TCAAGTTTGTG-3’)a n dt h ec-Myc cDNA vec-
tor (ATCC 5233860) as a template. Then the PCR pro-
ducts were cloned into pcDNA3.1/CT-GFP-TOPO
(Invitrogen) following the manufacturer’sp r o t o c o l ,
yielding pMYC-GFP. The c-Myc encoding sequence was
confirmed by DNA sequence analysis to be identical to
that of GenBank: BC000917.
A promoter/luciferase reporter construct containing
the BRCA1 promoter region (-1714 to +42) in pGL4.10
(Promega, Madison, WI) was generated as follows. The
required BRCA1 promoter region was amplified by PCR
using the primer pair: 5’-CTAGGTACC TTGGGAG
GGG GCTCGGGCAT GGC-3’ and 5’-CATAAGCTT
CCAGGAAGTC TCAGCGAGCT CACG-3’ (KpnI and
HindIII sites were underlined, respectively) and human
placental genomic DNA (Sigma-Aldrich, St. Louis, MO)
was used as a template. The PCR products were
digested with KpnI and HindIII, and the resulting frag-
ments were inserted into pGL4.10 at identical sites. The
resulting construct was named pCYL42. The inserted
DNA sequence of the BRCA1 promoter was determined
to be identical to that of GenBank: L78833 by DNA
sequence analysis.
We used a QuikChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) to generate E box nucleotide
substitutions following the manufacturer’sp r o t o c o l .T o
generate single E box nucleotide substitution constructs,
we used pCYL42 as the original template and corre-
sponding E box mX and E box mY primer pairs. The
primers (sense strands shown) used are shown below
with nucleotide substitutions underlined: E box mX: 5’-
AGATTGGCTC TTACAAAATG TCCCTCAAAA
CGAC-3’;a n dEb o xm Y :5 ’-GCGAGGGCTG CTA-
GAAAATT GTCACCTCGC ATTCT-3’. To generate
the double E box mutant, the mutagenesis reactions
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Y nucleotide substitution constructs as templates. All
constructs were confirmed by DNA sequence analysis.
The pMyc-TA-Luc and pTA-Luc plasmids used as c-
Myc activated promoter/luciferase controls were pur-
chased (Clontech Laboratories, Inc., Mountain View,
CA). The pMyc-TA-Luc vector is a derivative of pTA-
Luc and contains six tandem copies of the E box con-
sensus sequence (CACGTG) located upstream of the
minimal TA promoter, followed by the firefly luciferase
gene.
Small interfering RNA (siRNA)
All related reagents, including c-Myc siRNAs, control
siRNA, and transfection reagents, were purchased from
Qiagen (Valencia, CA). Transfections were performed
according to the manufacturer’s protocol.
Quantitative reverse transcriptase PCR
Total RNA was extracted from cultured cells using
the RNeasy mini kit (Qiagen). Reverse transcription
reactions were performed with the SuperScript III
First-Strand Synthesis System (Invitrogen) using 1 μg
of DNase-treated RNA and oligo (dT) primer. Real-
time PCR was performed in a Light Cycler (Roche
Diagnostics, Indianapolis, IN) using the LightCycler
FastStart DNA Master PLUS SYBR Green I kit (Roche
Diagnostics). Primers for BRCA1 and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH)w e r eu s e da s
previously described [9,28]. Thermal cycling for
amplification of BRCA1 or GAPDH was initiated by
heating at 95°C for 10 min, followed by 40 cycles of
denaturation at 94°C for 10 sec, annealing for 10 sec
at 54°C and 57°C for BRCA1 and GAPDH, respec-
tively, and elongation at 72°C for 15 sec. After com-
pletion of the PCR cycles, melting curve analyses and
electrophoreses of the products on 2% agarose gels
were performed to validate generation of each speci-
fic, expected PCR product. The fold change in BRCA1
cDNA (target gene) relative to the GAPDH control
was determined by the 2
-ΔCt method [29]. Experi-
ments were conducted independently twice in
triplicate.
Western blot
Western blotting was carried out as previously
described [30]. Mouse anti-BRCA1 antibody (AB-4,
Oncogene, San Diego, CA), mouse anti-c-Myc anti-
body (sc-40, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), and goat anti-actin antibody (sc-1616,
Santa Cruz Biotechnology, Inc.) were used for western
blotting. An ECL western blotting detection reagent
kit (GE Healthcare, Buckinghamshire, UK) was used
for detection.
Transient transfection and luciferase assay
One day prior to transfection, 6 × 10
5 cells were seeded
into one well of a six-well tissue-culture plate (BD Bios-
ciences, San Jose, CA). After 24 hours, cotransfections
were conducted. The transfection mixture contained a
promoter/luciferase reporter construct (980 ng), a
CMV/renilla luciferase vector, pGL4.75 (20 ng, Pro-
mega) as a transfection efficiency control, and an
expression construct for c-Myc (pMYC-GFP, 1000 ng or
other indicated amounts) or additional control vector
pcDNA3.1/CT-GFP (Invitrogen) to give consistent
amounts of total vector of 2000 ng. Then 6 μlo f
FuGENE HD (Roche Diagnostics) was added to the mix-
ture, and cotransfections were done according to the
manufacturer’s instruction. Forty-eight hours after trans-
fection, cell lysates were prepared using passive lysis
buffer (Promega). Luciferase activities in the lysates were
measured using a dual luciferase assay system (Promega)
with a 1450 microbeta trilux jet scintillation and lumi-
nescence counter (PerkinElmer Life and Analytical
Sciences, Downers Grove, IL). Experiments were per-
formed in triplicate.
In reporter assays with depletion of c-Myc in MCF-7
and MDA-MB-231 cells, 24 hours after siRNA treat-
ment, cotransfections were done using the mixture of
pCYL42 (1000 ng) and pGL4.75 (20 ng) combined with
2 μl of FuGENE HD as described above. Luciferase
activity was determined 48 hours after the transfection.
Experiments were performed in triplicate.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed following the manufacturer’s protocol (Upstate
Biotechnology, Lake Placid, NY) using 2 × 10
6 MCF-7
or MDA-MB-231 cells. An anti-c-Myc antibody (sc-764,
Santa Cruz Biotechnology, Inc.) or an anti-CTCF anti-
body (sc-15914, Santa Cruz Biotechnology, Inc) was
used to precipitate DNA-protein complexes, and the
normal isotype-matched IgG from the same species was
used as negative control. The PCR primers used for
detecting DNA fragments containing E boxes are: E box
X: ChIPX-FW: 5’-AATGCAAAGA CCGTCCGCTG
CCA-3’and ChIPX-RV: 5’-TCCACCCCTC AGCCCC
AGTG TTT-3’; E box Y: ChIPY-FW: 5’-TGAAG
GGCTC CTCCAGCACG-3’ and ChIPY-RV: 5’-TGAG
GGACCG AGTGGGCGAA-3’, and non E box:
ChIPNE-FW: 5’-CGAGAGACGC TTGGCTCTTT
CTGT-3’ and ChIPNE-RV: 5’-GCCCAGTTAT CTGA-
GAAACC CCAC-3’. The amplified PCR product size
was 233 bps for the detection of E box X, 146 bps for E
box Y, and 214 bps for non E box, respectively. The
band densities of the targeted PCR products were quan-
tified with the software QUANTITY ONE version 4.5.1
(Bio-Rad, Hercules, CA).
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We used a fluorescence-based DR-GFP reporter system
with modifications [31,32]. The efficiency of homolo-
gous recombination was assessed using a restriction
endonuclease I-SceI expression plasmid pCbASce and
pDR-GFP, an I-SceI repair reporter plasmid composed
of two differentially mutated GFP genes, one of which
contained a unique I-SceI restriction site. A double
strand break of DR-GFP plasmids created by I-SceI
digestion was repaired by gene conversion to produce a
functional GFP. The cells expressing GFP, representing
homologous recombination activity, were detected with
flow cytometry. Briefly, MDA-MB-231 cells were seeded
in a well of a six well plate. On the next day, the cells
were treated with equal amounts of siRNA against c-
Myc or control siRNA with Hiperfect as instructed by
the manufacturer (Qiagen). 48 hours later, pDR-GFP
plasmid, along with either pCbASce (expressing endonu-
clease I-SceI to create double strand breaks (DSBs)) or
pCAGGS (empty vector) were co-transfected into cells
by Fugene HD (Roche) as described above. After incuba-
tion for 48 hours, cells were trypsinized, harvested, and
finally suspended in PBS. Consequently, the cells were
analyzed at the flow cytometry facility of the University
of Chicago with a Becton Dickinson FCAScan (BD Bios-
ciences). The channel FL-1 (green) and FL-2 (orange)
were recorded and used to calculate the frequency of
GFP positive cells.
Statistical analysis
For quantitative RT-PCR, after logarithmic transforma-
tion, BRCA1 mRNA level was analyzed using ANOVA.
Then the regression coefficients were transformed back
to obtain the fold change or geometric mean difference
between study groups [33].
Means and standard deviations (SDs) were calculated
for relative luciferase activities, densitometry ratios, and
homologous recombinant efficiencies. Two-tailed Stu-
dent’s t-tests were used to compare only 2 groups.
ANOVA were implemented for comparisons with multi-
ple groups. After the overall analysis, Tukey tests were
used to make the pairwise comparison.
Results
The region -1714 to +42 of the BRCA1 promoter is
sufficient for response to c-Myc activation
BRCA1 has been implicated as a c-Myc target in a high
throughput study using human umbilical vein endothe-
lial cells overexpressing c-Myc [27]. Whether c-Myc can
directly regulate BRCA1 expression at the transcriptional
level is not clear. We successfully depleted c-Myc
expression in the breast cancer cell lines MCF-7 and
MDA-MB-231 through treatment with siRNA against
the c-Myc gene. In both cell lines, transient transfection
of c-Myc siRNA efficiently reduced c-Myc protein
expression (Figure 1A). Correspondingly, BRCA1 protein
levels were reduced upon depletion of c-Myc in both
cell lines (Figure 1A). More importantly, BRCA1 mRNA
levels in cells with depleted c-Myc protein were reduced
to 24% in MCF-7 and 36% in MDA-MB-231 compared
to the control siRNA treated cells (Figure 1B). To estab-
lish that BRCA1 expression was directly modulated by
c-Myc through DNA regulatory elements in the BRCA1
promoter region, we constructed a BRCA1 promoter/
luciferase reporter vector containing the BRCA1 promo-
ter region -1714 to +42. BRCA1 promoter activity fol-
lowing depletion of c-Myc was significantly reduced
compared to control in both cell lines (Figure 1C).
These data suggest that reduced c-Myc might decrease
BRCA1 expression in these two breast cancer cell lines
through the BRCA1 promoter. To test whether this
BRCA1 promoter region sufficiently responded to c-Myc
activation, we monitored BRCA1 promoter activity in
the presence of ectopically expressed functional c-Myc
from transient transfections of pMYC-GFP into MCF-7
or MDA-MB-231 cells. We observed increasing expres-
sion of the Myc-GFP with increasing amounts of Myc-
GFP expression vector used, while the endogenous c-
Myc expression remained consistent (Figure 2A). In
both cultured cell types, Myc-GFP protein levels pro-
duced at the maximal dose of the Myc-GFP expression
vector were similar to the levels of endogenous c-Myc
at the time when cells were used for luciferase assays
(Figure 2A). In the presence of constitutively expressed
Myc-GFP, BRCA1 promoter activity increased propor-
tionally to increasing amounts of pMyc-GFP (Figure
2B). Taken together, these data indicated that c-Myc
activates BRCA1 expression through the region of the
BRCA1 promoter (-1714 to +42), which could contain
c-Myc-mediated DNA regulatory elements.
Putative E boxes in the -1714 to +42 bp region of the
BRCA1 promoter
c-Myc regulatory sites within gene promoter regions,
such as the cognate hexanucleotide E box (CACGTG)
and non-cognate E boxes have been well documented,
but the DNA sequences of c-Myc binding regions could
be more degenerate [26]. In order to identify c-Myc
interacting elements, we used these E box sequences to
search for possible matches in the -1714 to +42 region
of the BRCA1 promoter, which is responsive to c-Myc
activation. Two nucleotide regions, -1292 to -1286 (E
box Y) and -912 to -907 (E box X), were found to be
either identical to or with high similarity to E box
sequences (Figure 3A). One nucleotide at position 4 of
E box X; (-909: G to T) differed from the cognate E box
sequence CACGTG, while seven nucleotides of E box Y
were identical to the non-cognate E box sequence
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Figure 1 Reduction of expressions of BRCA1 mRNA and BRCA1 protein, and BRCA1 promoter activity by depletion of c-Myc in breast
cancer cells. (A) MCF-7 or MDA-MB-231 cells were treated with c-Myc siRNA to deplete c-Myc expression, and total cellular c-Myc and BRCA1
protein levels were determined by western blot with actin levels serving as a protein loading control. (B) BRCA1 mRNA expression levels from
cells treated with c-Myc siRNA were determined by quantitative RT-PCR. Real-time PCR was performed in two independent experiments in
triplicate. Bars show mean ± SE. *: p < 0.01. (C) The BRCA1 promoter reporter vector pCYL42 was transfected into cells with depleted c-Myc by c-
Myc siRNA treatments, and BRCA1 promoter activities were recorded. The data were presented as means of control siRNA as 1, bars show mean
± SD. *: p < 0.01.
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Page 5 of 13CACGTTG. An alignment of the putative E boxes and
their adjacent regions is shown in Figure 3B. Almost
half of the nucleotides (12 to 30) were identical in two
DNA clusters, which indicated that these regions could
serve as a tandem array that facilitates c-Myc-containing
transcription factor binding (Figure 3B).
c-Myc forms complexes with E boxes of the BRCA1
promoter in vivo
The interactions between two E boxes of the BRCA1
promoter and c-Myc were investigated by an in vivo
ChIP assay. The cross-linked protein-DNA complexes
from cultured cells were immunoprecipitated with an
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Figure 2 Activation of BRCA1 expression by c-Myc in breast cancer cells. A vector of overexpression c-Myc (pMyc-GFP) and the reporter/
luciferase constructs were co-transfected into MCF-7 or MDA-MB-231 cells as describer in methods. The amounts of Myc-GFP expression vectors
are as indicated. (A) The constitutively expressed Myc-GFP fusion protein (Myc-GFP) and endogenous c-Myc (c-Myc) from the same amounts of
whole cellular protein extracts from each cell line are detected by western blot. Actins are used as the loading control (Actin). (B) BRCA1
promoter activities from whole cell lysates were measured. The luciferase data were normalized to the empty vector and compare to that
without overexpression of c-Myc as 1 (column: 0 ng). Bars show mean ± SD. *: p < 0.01 as each indicated column compared to the 0 ng
column.
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Figure 3 A diagram of BRCA1 promoter region and the alignment of regions spanning putative E boxes in the BRCA1 distal promoter.
(A) The diagram is an illustration only representing E boxes in BRCA1 gene distal promoter and is not to scale. Positions of putative E boxes are
marked by boxes with vertical lines, and regions of BRCA1 exon 1a and 1b (partial) are marked by filled boxes. The locations are relative to the
transcription start site of exon 1a as +1. (B) Nucleotides that are conserved between two of the E boxes (bold and italic) are shown as the
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Page 6 of 13anti-c-Myc antibody, and then DNA fragments were
released from immunoprecipitates. The c-Myc-asso-
ciated fragments were detected by semi-quantitative
PCR analysis using primers designed to amplify the
regions flanking each E box. Enrichment in fragments
containing either E box X; or E box Y were found in
immunoprecipitates treated with an anti-c-Myc antibody
in comparison to the control IgG, as detected by semi-
quantitative PCR using MCF-7 or MDA-MB-231 cells
(Figure 4A, X and Y panels). In MCF 7 cells, there was
nearly 4 or 5 fold increase in bound fragments contain-
ing E box X; or E box Y compared to the control IgG,
respectively as determined by densitometry quantifica-
tion. A similar enrichment was quantified in MDA-MB-
231 cells; almost 6 or 4 fold more for E box X; or E box
Y, respectively. There was no enrichment of PCR pro-
ducts in anti-c-Myc antibody-treated samples with pri-
mers designed to amplify a non E box region in BRCA1
promoter region, indicating this region was not asso-
ciated with c-Myc (Figure 4A, non E box panel). To
demonstrate the specificity of the E box X; or Y-c-Myc
interaction, we repeated the CHIP assay with CCCTC
binding factor (CTCF). CTCF binds to the BRCA1 pro-
moter and plays a crucial role in maintaining the methy-
lation-free state of the functional BRCA1 promoter
region [33]. Although CTCF binds to the BRCA1 proxi-
mal region as we previous reported [33], at E box X; or
Y there was no enrichment of targeted PCR products
when using anti CTCF antibody comparing that of con-
trol IgG (Figure 4B), suggesting CTCF was not asso-
ciated with these E boxes. These data strongly indicated
that c-Myc associates with these E boxes in breast can-
cer cells.
c-Myc activation of the BRCA1 promoter through E boxes
To determine if c-Myc-mediated BRCA1 activation is
dependent on E boxes X; and Y, we generated E box-
specific nucleotide substitutions in the BRCA1 distal
promoter. The pCYL42 promoter/reporter construct
was used as a parental vector and the E box sequences
CACTTG (E box X), or CACGTTG (E box Y) were
mutated to CAAAAG, or AAAATTG, respectively, with
nucleotide substitutions underlined. The BRCA1 promo-
ter/reporter activities were monitored in the presence of
constitutively expressed Myc-GFP. The activity of the
BRCA1 promoters containing nucleotide substitutions in
each E box was reduced compared to that of the wild-
type in MCF-7 or MDA-MB-231 cells (Figure 5A or 5C,
respectively). The promoter activity with double E box
nucleotide substitutions was decreased to a greater
degree (Figure 5A or 5C). To address the c-Myc depen-
dent activation by Myc-GFP, we used an E box promo-
ter/luciferase reporter construct, pMyc-TA-Luc, which
contained six tandem E box consensus sequences
inserted into pTA-Luc. The activity of the promoter
containing E boxes (E box-Luc), induced by constitu-
tively expressed Myc-GFP, was almost 3 times that of
the promoter without an E box (-Luc) (Figure 5B or 5D,
MCF-7 or MDA-MB-231, respectively). These observa-
tions and the results from the in vivo ChIP assay
described above indicate that E boxes in the BRCA1
promoter region are sufficient for c-Myc dependent acti-
vation in cultured breast cancer cells.
c-Myc dependent BRCA1 mediated DNA damage repair in
breast cancer cells
BRCA1 is involved in chromosomal stability and it has
been shown that BRCA1 deficient cells have impaired
DNA damage repair [34]. After showing that reduced c-
Myc expression led to decreased BRCA1 expression, we
tested whether depletion of c-Myc could abrogate the
BRCA1-mediated DNA repair function. We adopted a
well characterized GFP based double strand break repair
assay to monitor DNA repair activity. In this system,
screening cells for GFP expression following homolo-
gous recombination was used for testing DNA repair
activity. MDA-MB-231 cells were treated with c-Myc
siRNA (si-Myc) to deplete c-Myc thus correlated with
reduced BRCA1 expression, or control siRNA (si-ctrl)
(Figure 1). Then the DR-GFP reporter system in various
combinations was introduced into cells. 48 hours later
the green fluorescence in the cells was monitored by a
flow cytometer. The GFP positive cells were identified
after the FL-1 (green fluorescence) vs FL-2 (orange
fluorescence) ratio. The representative analyses for each
condition of DR-GFP reporter system were depicted as
A, B, C, or D and the summary of three triplicate
experiments was shown in E. The control siRNA treated
cells with intact BRCA1 exhibited considerable homolo-
gous recombination efficiency (HR efficiency) (Figure
6C, D, and 6E, si-ctrl). A significant reduction of HR
efficiency was observed when c-Myc was depleted by c-
Myc siRNA treatment compared to the cells with con-
trol siRNA (Figure 6A, C and, Figure 6E, black column
vs blank column). A slightly higher DNA repair activity
was evident between the cells in the presence of I-SceI
and without I-SceI even both cells were treated with c-
Myc siRNA (Figure 6A, B, and 6E, si-c-Myc), indicating
cells still maintained HR activity at certain level even
with reduced BRCA1. No significant difference in HR
efficiency was found between c-Myc siRNA and control
siRNA treated cells without I-SceI introduced DSBs
(Figure 6B, D, and 6E, horizontal vs vertical lined
column).
Discussion
In the present report, we used a targeted identification
strategy for characterizing regulatory DNA elements to
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Figure 4 c-Myc associates with the BRCA1 promoter regions containing E boxes in vivo. (A) Cross-linked protein-DNA complexes with
formaldehyde were incubated with an anti-c-Myc antibody or control IgG. After immunoprecipitation, DNA is recovered from the protein-DNA
complex, and the DNA fragments were subjected to PCR with a primer pair specific for detecting the distal BRCA1 promoter regions containing
E box X, or E box Y, and indicated as panel X, or panel Y, respectively. Detection of a random region in BRCA1 promoter was shown as non E
box panel. (B) An anti-CTCF antibody or control IgG were used for immunoprecipitation of CTCF bound protein-DNA complex, and the DNA
fragments recovered were subjected to PCR for detecting regions containing E box X, or E box Y. An aliquot (1%) of total DNA without
immunoprecipitation was used for input. The PCR products were analyzed by 2% agarose gel electrophoresis, and stained with ethyl bromide.
The cell lines, specific antibodies, and targeted PCR fragments were indicated. The experiments were done three times and all produced similar
results. The representative targeted PCR product images are depicted, and bars show mean ± SD. *: p < 0.01 as c-Myc compared to IgG.
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Page 8 of 13show transcriptional activation of BRCA1 by c-Myc
through c-Myc’s interaction with two E boxes in the dis-
tal BRCA1 promoter region. Genome-wide analysis has
shown that c-Myc could bind to the regulatory regions
of up to 15% of all human genes, and these data also
indicated that c-Myc-DNA interactions were not suffi-
cient for promoter regulation in some cases [35,36].
Indeed, it has been shown that although c-Myc binds to
the CCL5 gene promoter in both MCF-7 and MDA-
MB-231 cells, c-Myc-dependent regulation of CCL5 was
evident in MCF-7 but not in MDA-MB-231 cells. Con-
sistently, gene expression profiling analysis has shown
that the spectrum of genes regulated by c-Myc in these
cell lines is intrinsic to each cell line [37]. While the
mechanism of how c-Myc functions in such a cell con-
text-dependent manner is not clear, possibilities include,
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Figure 5 E boxes in the BRCA1 promoter are required for BRCA1 activation by constitutively expressed c-Myc. MCF-7 or MDA-MB-231
cells (A or C, respectively) were transiently co-transfected with Myc-GFP expression vector along with the BRCA1 promoter (pCYL42, FL) or its
derivates with E box nucleotide substitutions (X, Y, or XY) as described in methods. Luciferase activities from cell lysates were determined 48
hours after transfection. The fold changes were normalized to the vector control and the full-length BRCA1 promoter activities set as 1. *: p <
0.01. The activation of a promoter/reporter construct containing six tandem E boxes (E box-luc) by constitutively expressed Myc-GFP was used as
a control [B or D (MCF-7 or MDA-MB-231, respectively)]. Bars show mean ± SD. *: p < 0.01 as each indicated column compared to the FL
column in A or C, and to -luc column in B or D.
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Figure 6 Examination of HR activity using DR-GFP reporter. MDA-MB-231 cells were treated with c-Myc siRNA or control siRNA, then the
DR-GFP reporter plasmids with different combinations were co-transfected into cells as indicated in E. The percentage of GFP positive cell was
determined by a flow cytometer using detector FL-1 (green) vs FL-2 (orange), the HR efficiency represented as the frequency of GFP-positive cell.
The representative analysis for each treatment depicts as A, B, C, or D along with the percentage of GFP positive cells due to gene conversion as
E. Bars show mean ± SD. *: p < 0.01 as compared with paired groups indicated.
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Page 10 of 13but are not limited to, post-translational modifications
of c-Myc. For example, phosphorylation and acethyla-
tion of c-Myc could affect its protein-DNA and protein-
protein interactions, which would contribute to its selec-
tive binding of target gene promoters. Recently Benassi
et al. showed that phosphorylation of S62 of c-Myc
could increase its binding ability to the promoter region
of the g-glutamyl cysteine synt h e t a s eg e n e[ 3 8 ] .H o w -
ever, the conclusive connections between c-Myc-DNA
binding abilities and c-Myc transcriptional activities in a
given condition are still obscure, as in the case of the
CCL5 g e n e .I nt h i ss t u d y ,w ei d e n t i f i e dt w oEb o x e s
within the BRCA1 promoter region and provided evi-
dence that these were necessary for c-Myc-dependent
promoter activation in MCF-7 and MDA-MB-231 cells
(Figure 1). Although the co-factors recruited by c-Myc
to these sites were not elucidated in our present experi-
ments, we speculate that it is highly likely that a c-Myc-
containing transcription complex would play an impor-
tant role in BRCA1 expression.
Our data showed that BRCA1 activation by c-Myc only
increased promoter activities by 1.8 fold under the condi-
tions used (Figure 2B), and disrupting c-Myc-responsive
elements (two E boxes) by different combinations corre-
lated with loss of promoter activity ranging from 30-40%
(Figure 5A and 5C). This observation is consistent with a
previous report that BRCA1 mRNA expression was
detectable in c-Myc knockout c-Myc
-/- Rat1A cells, and
expression of c-Myc by serum stimulation in the parent
c-Myc
+/+ Rat1A cells slightly increased BRCA1 mRNA
expression [27]. BRCA1 expression activated by c-Myc
could be the final outcome of the interplay within multi-
component transcriptional networks containing factors
important for breast tumorigenesis. It has been shown
that HIF-1a transcriptional machinery activated by
hypoxia signaling pathway abrogates c-Myc activation of
BRCA1 expression in colon cancer cells [39]. c-Myc acti-
vates the expression of p53 t h r o u g ha nEb o xw i t h i nt h e
p53 promoter [40]. On the other hand, p53 represses c-
Myc transcription by binding to the c-Myc promoter and
recruiting the general repressor mSin3a; this repression is
required for cell cycle arrest and differentiation but not
apoptosis [41]. In addition, p53 up-regulates ER-a by
increasing gene transcription [42]. c-Myc is up-regulated
by activated ER-a and plays a critical role in enhancing
estrogen-induced breast cell proliferation [43,44].
Although not directly mediated by the ER-a pathway,
estrogen stimulation up-regulates p53 expression [45].
Thus, further studies to elucidate transcription factor
occupancy on the BRCA1 promoter, including proximal
and distal regions, in breast cancer cells with distinct
molecular signatures would be critical to understanding
the complex regulation of BRCA1 expression during
tumor progression.
Accumulating evidence has demonstrated that BRCA1
is a major component of the DNA damage repair com-
plex required for normal cellular processes. Depletion of
BRCA1 has been associated with decreased DNA damage
repair and increased chromosomal instability [46]. In
order to maintain the basal level of DNA damage repair,
BRCA1 may be required for c-Myc associated cell prolif-
eration. In this report we show that c-Myc can activate
BRCA1 expression in breast cancer cells, and depletion of
c-Myc reduced BRCA1-dependent DNA repair. However,
the complicated interaction between c-Myc and BRCA1
may be cell context dependent. In breast cancer patients,
c-Myc amplification was found more often in patients
with BRCA1 deficiency than in patients with normal
BRCA1 [47], suggesting that c-Myc amplification could
be linked to decreased BRCA1 but the mechanism is
poorly understood. These data suggested that c-Myc
overexpression and BRCA1 loss seemed highly correlated
in a large portion of basal-like breast cancers. This could
indicate that loss of BRCA1 with c-Myc overexpression
might lead to the development of basal-like breast cancer.
Interestingly, we have reported that reduction of BRCA1
expression could be due to BRCA1 promoter methylation
[9]. c-Myc has been shown to recruit DNA methyl trans-
f e r a s e ss u c ha sD N M T 3 at or e p r e s sp 2 1 C i p 1g e n e
expression [48]. It raises the questions of c-Myc’si n v o l -
vement in the DNA methylation complex in breast can-
cer cells; particularly if BRCA1 is a target. It is worth
noting that aberrant expression of DNA methyl transfer-
ase or its alternative splicing forms have been detected in
cancerous cells, and could affect the distribution of DNA
methylation [49].
A l t h o u g ho u rd a t as u p p o r tam o d e li nw h i c hBRCA1
expression is regulated by transcription factors, such as
c-Myc, it has been shown that other mechanisms could
also affect BRCA1 expression. Epigenetic regulation such
as BRCA1 promoter methylation has been shown to
account for BRCA1 loss in 10-31% of sporadic breast
cancer tumors [9]. The accessibility of transcription fac-
tors to the methylated BRCA1 promoter is reduced, and
consequently the expression of BRCA1 mRNA and
BRCA1 protein is decreased [33]. On the other hand,
nucleosome occupancy has been identified as an alterna-
tive means to regulate BRCA1 expression [50]. Taken
together, chromatin structure, methylation status of the
gene promoter and dynamic transcription factor recruit-
ment may work together to affect BRCA1 expression in
breast cancer cells. Newly identified regulation by means
of microRNA could also play a role in BRCA1 expres-
sion at the translational level. Aberrant expression of a
s e to fm i c r o R N A sh a v eb e e nf o u n di nb r e a s tt u m o r
samples, and some of these microRNAs could target
BRCA1 mRNA [51], thus possibly regulating BRCA1
expression.
Chen et al. BMC Cancer 2011, 11:246
http://www.biomedcentral.com/1471-2407/11/246
Page 11 of 13Conclusions
Previous data from our lab and others have shown that
BRCA1 expression in breast cancer was regulated at epi-
genetic and transcriptional levels. The data presented
here suggests c-Myc is a novel member of transcription
activators for BRCA1 expression. This study showed
that the E boxes in the distal BRCA1 promoter region
contribute to BRCA1 gene activation, and this activation
is dependent on c-Myc. Our data suggest a transcrip-
tional link between c-Myc and BRCA1, which has con-
sequences for BRCA1 dependent-DNA damage repair.
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